The cytochromes P450 (CYPs) comprise a vast superfamily of enzymes found in virtually all life forms. In mammals, xenobiotic metabolizing CYPs provide crucial protection from the effects of exposure to a wide variety of chemicals, including environmental toxins and therapeutic drugs. Ideally, the information on the possible metabolism by CYPs required during drug development would be obtained from crystal structures of all the CYPs of interest. For some years only crystal structures of distantly related bacterial CYPs were available and homology modelling techniques were used to bridge the gap and produce structural models of human CYPs, and thereby obtain useful functional information. A significant step forward in the reliability of these models came seven years ago with the first crystal structure of a mammalian CYP, rabbit CYP2C5, followed by the structures of six human enzymes, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6 and CYP3A4, and a second rabbit enzyme, CYP2B4. In this review we describe as a case study the evolution of a CYP2D6 model, leading to the validation of the model as an in silico tool for predicting binding and metabolism. This work has led directly to the successful design of CYP2D6 mutants with novel activity-including creating a testosterone hydroxylase, converting quinidine from inhibitor to substrate, creating a diclofenac hydroxylase and creating a dextromethorphan O-demethylase. Our modelling-derived hypothesis-driven integrated interdisciplinary studies have given key insight into the molecular determinants of CYP2D6 and other important drug metabolizing enzymes.
Introduction
The cytochromes P450 (CYPs) comprise a vast superfamily (46000 known members (Nelson, 2007) ) of haem-containing mono-oxygenase enzymes found in virtually all life forms. Members of this ubiquitous superfamily play an important role in the metabolism and biosynthesis of a wide range of exogenous and endogenous compounds (Nebert and Russell, 2002) . In mammals, these enzymes are involved, among other things, in the metabolism of xenobiotic compounds-including environmental toxins and therapeutic drugs. One of the most interesting characteristics of the CYPs is their promiscuity. Individual isoforms are capable of interacting with a wide range of chemically diverse substrates, and some CYPs have overlapping substrate specificities. This promiscuity is useful in terms of defence of the organism against potentially harmful xenobiotics, but in some instances can lead to rapid drug clearance/inactivation, production of toxic compounds and/or adverse drug-drug interactions. The three-dimensional (3D) structure of a protein-particularly in complex with ligand(s) of interest-can provide valuable insight into its function. Therefore, it is desirable to have available structures of the drug-metabolizing CYPs. Co-crystallization of CYPs with known inhibitors and substrates can give insight into protein-ligand interactions in the active site, and from this allow the inference of likely metabolites, how modifications to the ligand and/or enzyme structure may potentially affect CYP-ligand binding, and if there is scope for adverse ligandligand interactions. All of this information provides a direct empirical means of assessing and predicting the potential fate of compounds. However, the structures of a substantial number of CYPs remain to be determined experimentally. In these cases, homology (comparative) modelling (Kirton et al., 2002a) can be used to give insight into the structure. The premise underpinning homology modelling arises from the observation that proteins with similar amino-acid sequences have a tendency to adopt similar 3D structures (Chothia and Lesk, 1986 ). Therefore, it is possible to predict the 3D structure of a protein based solely on knowledge of its amino-acid sequence and the 3D structures of proteins with similar sequences.
In humans, 90% of all of the drugs currently approved for clinical use are metabolized by one of seven CYP isoforms, CYP1A2, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1 and/or CYP3A4 (Tanaka, 1998; Guengerich, 2001; Nebert and Russell, 2002) . Of these isoforms, CYP2D6 and CYP2C9 display polymorphisms that can result in the poor metabolism of drugs (Mahgoub et al., 1977; Kroemer and Eichelbaum, 1995; Sullivan-Klose et al., 1996; Aithal et al., 1999; Kidd et al., 1999 Kidd et al., , 2001 Takahashi and Echizen, 2001) . Having knowledge of the structural features of the active sites of these seven isoforms in particular could lead to a tool that was able to predict whether or not a drug candidate would interact with the CYPs and, if so, which isoform the drug candidate may interact with preferentially. This would impact on the rational design of improved therapeutic drugs and target-specific inhibitors. It would also affect the risk assessment of xenobiotics and the avoidance of adverse drug-drug interactions, whereby one drug modulates the metabolism of another (Tanaka, 1998) by simple competition for the same active site, and/or by binding in an allosteric region of the same enzyme. Knowledge of the active site structure for these enzymes will significantly reduce the failure rate in clinical trials by identifying any CYP liabilities in the early stages of drug development, and reduce the amount of time and money required to bring a new pharmaceutical to the market.
Over the years, many homology models of the CYPs have appeared in the literature (de Groot et al., 2004) . Until the year 2000, all structural models for the human CYPs were based on the X-ray crystal structures of distantly related bacterial CYP isoforms. In 2000, a major breakthrough was achieved with the determination of the structure of the first mammalian CYP, that of the rabbit enzyme CYP2C5 (Williams et al., 2000) . This structure was more closely related to the human isoforms than the bacterial isoforms, and by incorporating the new structure into homology modelling studies, the quality and accuracy of the homology models of the human CYPs was vastly improved (Kirton et al., 2002b) . Recently, the determination of X-ray crystal structures for several human isoforms important in drug metabolism (CYP1A2 (Sansen et al., 2007) , CYP2A6 (Yano et al., 2005) , CYP2C8 , CYP2C9 (Williams et al., 2003; Wester et al., 2004) , CYP2D6 (Rowland et al., 2006) and CYP3A4 (Williams et al., 2004; Yano et al., 2004) ) has removed the need for homology models in some instances and has also, together with the availability of a second rabbit crystal structure (CYP2B4) (Scott et al., 2003 (Scott et al., , 2004 , improved the quality of models for the other human isoforms.
We give an overview of the techniques used for modelling the 3D structures of human CYPs and CYP-drug interactions, presenting the development and validation of a model of CYP2D6, and comparison with the subsequently determined crystal structure of CYP2D6, as a case study.
CYP2D6
The CYP2D6 isoform plays a central role in drug metabolism in humans. It is responsible for the clearance of at least 20% of the compounds in current clinical use, including antiarrhythmics, antidepressants, antipsychotics, b-blockers and analgesics (Kroemer and Eichelbaum, 1995) . This isoform is of particular interest to the pharmaceutical industry because it displays a genetic polymorphism, the consequence of which is large interindividual and ethnic differences in the drug metabolism mediated by CYP2D6. This is highlighted by the defect in man known as debrisoquine/sparteine polymorphism (Mahgoub et al., 1977; Eichelbaum et al., 1979) . This polymorphism can arise from one of several genetic mutations and affects a significant proportion of the Caucasian population (Daly et al., 1995) . It results in the defective metabolism of a number of clinical drugs, and inheritance of the 'poor-metabolizer' phenotype has been linked with an increased susceptibility to Parkinson's disease and certain types of cancer (Eichelbaum et al., 1979; Smith et al., 1995) . Consequently, many pharmaceutical companies are interested in designing drug candidates that are not metabolized by CYP2D6. Understanding the structure of CYP2D6 and potential protein-ligand interactions would aid in this rational design of potential drug candidates. Prior to the elucidation of the X-ray crystal structure, this was assisted by homology models.
Early models of CYP2D6 based on bacterial CYPs
A feature common to the vast majority of CYP2D6 substrates is the presence of a basic nitrogen atom and a planar aromatic ring. Since these features are also found in a large number of central nervous system and cardiovascular drugs (which act on G protein-coupled receptors), CYP2D6 has been a very widely studied isoform. Prior to the availability of crystal structures of mammalian CYPs, models of human CYPs were based on the structures of more distantly related bacterial CYPs-these share less than B25% sequence identity with CYP2D6. Based on the observation that sequence alignment becomes difficult in the 'twilight zone' of less than 30% sequence identity (Rost, 1999) , this led to the belief in some quarters that such homology models would not shed any useful light on the function of CYP2D6. However, this pessimism proved unjustified.
Many models of the active site of CYP2D6 postulated the involvement of a carboxylate group in the protein forming a salt bridge with this basic nitrogen (Meyer et al., 1986; Islam et al., 1991; Koymans et al., 1992; de Groot et al., 1996 de Groot et al., , 1999 Modi et al., 1996 Modi et al., , 1997 Lewis et al., 1997; Lewis, 1999; Venhorst et al., 2003) ; this was proposed both by modelling and by mutagenesis (Mackman et al., 1996) to be Asp301, a residue in the I-helix (substrate recognition site (SRS4; Gotoh, 1992) . The recently determined crystal structure of CYP2D6 (Rowland et al., 2006 ) has confirmed such a role for Asp301 in ligand binding (but see Discussion below).
Our early models (Modi et al., 1996 (Modi et al., , 1997 ) (produced using Modeller (Sali and Blundell, 1993) ; see Kirton et al., 2002a for more details) were also used in conjunction with sequence analysis to design a CYP2D6 mutant, F483I, based on the presence of an isoleucine in this position in testosteronemetabolizing CYP2D9, with novel specificity, able to metabolize testosterone (Smith et al., 1998) . That Phe483 is in the binding site is confirmed by the crystal structure (Rowland et al., 2006) . Mutagenesis data (Hayhurst et al., 2001b; Chowdry et al., 2002) suggested that, together with Phe483, Phe481 also has a detrimental impact on the oxidation of debrisoquine. While in our models (Modi et al., 1996 (Modi et al., , 1997 and in the crystal structure (Rowland et al., 2006) Phe481 is removed from the active site, constrained molecular dynamics simulations (based on the crystal structure) show that this loop can alter conformation so that both phenylalanines are in the active site (Rowland et al., 2006) . Thus, despite the low level of sequence homology between CYP2D6 and the bacterial CYP templates-and concomitant concern about the quality of the models-some useful information was accurately gleaned even from these early models.
Models of CYP2D6 based on mammalian CYPs
The determination of the first crystal structure of a mammalian CYP-rabbit CYP2C5 (Williams et al., 2000; Wester et al., 2003a, b) , which shares B40% sequence identity with CYP2D6-paved the way for more accurate CYP2D6 models. Our 'second-generation' CYP2D6 model (Kirton et al., 2002b) (that is, including at least one mammalian CYP as a template) was generated using the rabbit CYP2C5 crystal structure as a template alongside the four bacterial templates P450cam (Poulos et al., 1986) , P450BM-3 (Ravichandran et al., 1993) , P450terp (Hasemann et al., 1994) and P450ery-F (Cupp-Vickery et al., 2000) . To evaluate the predictive value of this CYP2D6 model, docking studies were carried out using the program GOLD (Jones et al., 1997) on known substrates of CYP2D6, including codeine (Kirton et al., 2002b) , 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Kirton et al., 2002b) , dextromethorphan and spirosulphonamide . In each case, the docking was consistent with the known site of metabolism (that is, the highest ranked docked solution positioned the known site of metabolism above the iron atom of the haem moiety).
Role of Glu216 and Asp301
Codeine was observed to dock in the active site of the CYP2D6 model (Kirton et al., 2002b) in an orientation consistent with O-demethylation (Desmeules et al., 1991; Ladona et al., 1991; Kirton et al., 2002b) . Surprisingly, the docking did not position the basic nitrogen atom of the substrate close to Asp301. Instead, the basic nitrogen was observed to interact with a second acidic residue in the active site, Glu216 (in the F-helix, SRS2); the proposed role of Glu216 was further supported by analysis of the active site using GRID (Goodford, 1985) probes. The model suggests that Asp301 is not involved directly in substrate binding but plays a structural role positioning the B-C loop (SRS1), including Phe120 (see below)-this hypothesis was subsequently verified when the crystal structure of CYP2D6 was determined (Figure 1 ; Rowland et al., 2006) . The docking results for MPTP (Kirton et al., 2002b) and dextromethorphan also positioned the basic nitrogen atoms of the substrates close to Glu216 and away from Asp301.
An independent study also suggests that Asp301 plays a structural role (Hanna et al., 2001) , and an analysis of 431 CYP sequences (Kirton et al., 2002b) indicates that specificity for basic substrates requires acidic residues equivalent to both Asp301 and Glu216. The proposed key role of Glu216 was confirmed by experiment (Paine et al., 2003) . Indeed, the mutation of Glu216 altered the specificity to such an extent that metabolism of testosterone was observed (Paine et al., 2003) . Furthermore, the E216Q/D301N double mutant acts on 'atypical' substrates (Paine et al., 2003) , including anionic compounds such as diclofenac, 'classic' substrates of CYP2C9. This suggests that the binding site of CYP2D6 is thus intrinsically rather promiscuous, with Glu216 and Asp301 favouring the binding of basic substrates and discriminating against acidic substrates.
We have also shown that Glu216 and Asp301 play a key role in the action of quinidine as an inhibitor of CYP2D6 McLaughlin et al., 2005) . Quinidine is not metabolized by CYP2D6 and has long been established as a potent competitive inhibitor of this enzyme (von Bahr et al., 1985; Guengerich et al., 1986 Guengerich et al., , 2002b Otton et al., 1988; Branch et al., 2000) . The fact that quinidine is an inhibitor rather than a substrate is intriguing, since it produces a classical type I binding spectrum with CYP2D6 (Hayhurst et al., 2001a) that is usually associated with the binding of substrate molecules (Schenkman et al., 1981) . In addition, quinidine possesses a number of features normally associated with CYP2D6 substrates (Strobl et al., 1993) . Studies of the relationship between structure and inhibitory activity for quinidine and its (less potent) stereoisomer quinine have been reported (Hutzler et al., 2003) , but we have only recently established the protein-ligand interactions, which are responsible for the fact that quinidine can bind tightly but not in an orientation favourable for catalysis (McLaughlin et al., 2005) . We used homology modelling and molecular docking to predict the modes of quinidine binding to wild-type and mutant enzymes (McLaughlin et al., 2005) . In contrast to the wild-type enzyme (Figure 2a) , the E216F mutant produced O-demethylated quinidine (Figure 2b) , and E216Q/D301Q produced both O-demethylated quinidine and 3-hydroxyquinidine metabolites (McLaughlin et al., 2005) .
The crystal structure of CYP2D6 (Rowland et al., 2006) supports a ligand-binding role for both Glu216 and Asp301 (Figure 1 ). However, it is suggested that since in this structure the trans and gauche À rotameric states of Asp301 can account for all the pharmacophoric models, Glu216 is more likely to act as a recognition residue that attracts basic ligands to the active site, where it forms an intermediate binding site prior to the ligand adopting a more 'reactive' position in the cavity. Such a suggestion is similar to the intermediate binding pocket occupied by warfarin in the crystal structure of the S-warfarin/CYP2C9 complex (Williams et al., 2003) , but apparently inconsistent with the mutation E216F transforming CYP2D6 into a quinidine demethylase. Resolution of this issue awaits co-crystallization of substrates in CYP2D6. conjunction with molecular modelling, the role of this residue in substrate binding and catalysis was investigated . The results show the aromatic moiety of Phe120 does indeed have a steric influence on the orientation of molecules in the active site of CYP2D6, and therefore plays a role in controlling the regioselectivity of substrate oxidation. This is further supported by our studies of quinidine metabolism by mutant CYP2D6 (see also above). Unlike wild-type CYP2D6, the F120A mutant produced both O-demethylated quinidine and 3-hydroxyquinidine metabolites (Figures 2c and d ; ). Our results suggest that Phe120, positioned close to the haem iron, is a key factor in controlling access to the haem.
Role of Phe120
In accord with our modelling results, the crystal structure also suggests a role for Phe120 in controlling the orientation of substrates with respect to the haem (Rowland et al., 2006) . Analysis of the CYP2D subfamily (Figure 3 ) reveals that CYP2D enzymes require a hydrophobic residue in this position, although an equivalent bulky residue occurs in only a small number of CYP2D enzymes. This observation suggests that most other CYP2D enzymes will exhibit different drug disposition profiles from that of CYP2D6. Interestingly, a small percentage of the southeast Asian population have a polymorphic CYP2D6 containing the mutation F120I (Solus et al., 2004) , suggesting modified drug metabolism and disposition in these individuals.
Binding of atypical substrates
The ability of CYP2D6 homology models to predict the binding modes of substrates devoid of a basic nitrogen, for example spirosulphonamide, has been questioned (Guengerich et al., 2002a) . To investigate if our CYP2D6 model is predictive with this type of substrate, the substrate spirosulphonamide was docked into our CYP2D6 model . The highest ranked docked solution positioned the cyclopentyl moiety above the haem and hence correctly identified a major metabolite (Guengerich et al., 2002a) , providing additional validation of our model.
Binding affinities
We have also tested the ability of our model and docking approach to predict CYP2D6 inhibition-a group of 33 compounds from the National Cancer Institute database was docked into our CYP2D6 model, and experimental IC 50 values for the compounds were determined; comparison of the experimental and predicted affinities revealed a correlation with a regression coefficient of r 2 ¼ 0.61 (q 2 ¼ 0.59) . This level of success is noteworthy in itself, and more so because the dockings were into a model rather than a crystal structure. Binding affinities are notoriously difficult to predict quantitatively, and a docking study on 11 different P450cam-ligand complexes (Keseru, 2001) found no clear correlation between experimental and predicted affinities. Our approach is able to discriminate between tightly and weakly binding compounds and correctly identified several novel inhibitors.
Comparison with crystal structure of CYP2D6 When the crystal structure of CYP2D6 (Rowland et al., 2006) became available, we were also able to validate our model against this. There is good agreement between residues in the substrate-binding site (as mentioned above for specific residues), with those residues within 5 Å of the haem overlaying almost perfectly. The overall Ca RMSD (root mean square deviation of alpha carbon atoms) between the model and the crystal structure is (a very reasonable) 0.8 Å .
One key difference is in the F-G loop region-a region that varies in size and shape across different CYPs-which arises because this region is in a different conformation in the structural templates used for modelling to that in the crystal structure. This highlights an important limitation of homology modelling-that the structure of the model is generally limited to the structural space occupied by the templates used. Such issues can be (partially) addressed using, for example, loop modelling or molecular dynamics simulation. Additional challenges are faced by conformational changes that may occur on substrate binding, for example, the 480% increase in active site volume that can occur in CYP3A4 (Ekroos and Sjogren, 2006) . Such changes are difficult to predict and difficult to address using molecular dynamics simulations.
B'-helix C-helix 120 | Figure 3 The B 0 -C region (SRS1) of CYP2D subfamily members. The residue position corresponding to Phe120 in CYP2D6 is boxed. Species and Swissprot accession codes are as follows: CYP2D6: human, P10635; CYP2D1: rabbit, P10633; CYP2D2: rat, CP2DQ; CYP2D3: rat, P12938; CYP2D4: rat, P13108; CYP2D7: human, Q6XP50; CYP2D9: mouse, P11714; CYP2D10: rat, P12938; CYP2D11: mouse, P24457; CYP2D13: mouse, Q8XC0; CYP2D14: bull, Q01361; Cyp2D15: dog, Q29473; CYP2D16: guinea-pig, Q64403; CYP2D17: macaque fascicularis, Q29488; CYP2D18: rat, Q64680; CYP2D19: marmoset, O18992; CYP2D20: golden hamster, Q9QYG5; CYP2D21: domestic pig, Q6LEL6; CYP2D23: rabbit, Q9TUJ4; CYP2D25: domestic pig, O46658; CYP2D26: mouse, Q8CIM7; CYP2D27: golden hamster, Q9QYG6; CYP2D28: golden hamster, Q9QUJ1; CYP2D30: marmoset, Q865W1.
Drug-drug interactions
Additionally, we used our model to investigate drug-drug interactions in CYP2D6 with drugs commonly taken by patients with cancer as part of a co-medication regime . This study uncovered the correct metabolite for metoclopramide, a drug frequently used to prevent the nausea and vomiting associated with cancer chemotherapy (Harrington et al., 1983) . Our study also suggested a particular CYP2D6 genotype/phenotype for those experiencing adverse reactions with metoclopramide, for example extra-pyramidal syndrome (Pall and Williams, 1987) . The general applicability of our approach is illustrated by our modelling study of the interaction of anticancer comedication drugs with CYP3A4 . The commonly prescribed drugs loperamide, amitriptyline, diltiazem, domperidone, lansoprazole, omeprazole and simvastatin were correctly identified by our in silico screens as relatively potent inhibitors of CYP3A4 , highlighting the likelihood of drug-drug interactions affecting chemotherapy treatment.
Concluding remarks
Using CYP2D6 as an example it is clear that a relatively 'simple' in silico approach-combining homology modelling with molecular docking, active site characterization and bioinformatics analysis-can predict the sites of metabolism of a range of known substrates, and successfully identify key residues for substrate recognition and binding in the active site. It is also evident, initially from mutagenesis studies and more recently by comparison with the recently available crystal structure of CYP2D6, that high-quality homology models can give a range of insights into the mechanism of an enzyme, and from this infer possible metabolic consequences for compounds of interest. However, it is important to remember that caution must be exercised in the initial stages of model building by ensuring that an accurate amino-acid sequence alignment is obtained-aided by a good working knowledge of the enzyme, which can be enhanced significantly when integrated with synergistic experimental studies. The real strength of this approach is in enriching the success of experimental studies by reducing the number of non-productive 'dead ends'.
